GT Biopharma Inc. Common Stock (GTBP)

About GTBP

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1

Website

www.gtbiopharma.com

Fundamentals

1-day range

$0.2871$0.3062

Market cap

$13.35M

P/E (trailing)

—

P/E (forward)

-0.03

EPS (trailing)

$-6.46

Dividend yield

—

Beta

0.90

Avg. volume

1.16M

Dividend pay date

August 21, 2017

Forecasts

1 analyst ratings

GT Biopharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• GTBP

  GT Biopharma Inc. Common Stock

  $0.3

  ▼ 0.66%
  Market cap $13.35MP/E —
  $0.261$1.53
• PBM

  Psyence Biomedical Ltd. Common Shares

  $4.21

  ▼ 3.44%
  Market cap $13.31MP/E —
• CMMB

  Chemomab Therapeutics Ltd. American Depositary Share

  $2.7

  ▼ 0.74%
  Market cap $12.95MP/E —
  $1.35$3.78
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $13.80MP/E —
  $0.1772$1.45
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.00MP/E 85.09
  $5.61$31
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $14.14MP/E Infinity
  $3.02$49.6
• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $14.20MP/E —
  $0.76$2.67

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
  Benzinga · 8/14/2026

Institutional Ownership

March 31, 2026

Total shares held

1.37M

Total value held

$538.1K

Institutional holders

39